Relaunch of TruScreen Devices in Xinjiang Uygur Region

NZX/ASX Announcement
10 August 2022
China Distributor Relaunches TruScreen devices in Xinjiang Uygur
Autonomous Region
Key Highlights
• TruScreen distributor Beijing Siweixiangtai Tech Co Ltd (SWXT) has relaunched distribution for
the Xinjiang Uygur Autonomous Region (UAR)
• Project was previously put on hold and further delayed by COVID
• Xinjiang Regional price approval for the TruScreen device was previously approved for Xinjiang
UAR in 2020
• Xinjiang UAR in China’s far north-west has 26 million people over a vast area of 1.7m Km²
• Initial order of 20 TruScreen (China assembled) cervical cancer screening devices and 12,960
SUS has been delivered

TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company’) is pleased to announce that its
China distributor Beijing Siweixiangtai Technology Company Ltd (SWXT) has relaunched distribution of
TruScreen cervical cancer screening device to Xinjiang Uygur Autonomous Region.
With easing of COVID restrictions, the relaunch of distribution in Xinjiang UAR resumes the policy focus of
China’s Central and Provincial governments to continue with their national cervical cancer screening
programmes to achieve the World Health Organisation’s strategic screening targets by 2030 and of eliminating
cervical cancer by the end of the century.
The Xinjiang UAR has a population of 26 million spread over an area of 1.7 million Km². This vast area has
many ethnic minority groups in remote locations with the Xinjiang UAR government providing special funding
for cancer screening programmes.
The TruScreen cervical cancer screening device is ideally suited for Xinjiang UAR and has significant
advantages in undertaking cervical cancer screening programmes in this vast area with many remote locations.
The ability to provide a real time result with a robust TruScreen cervical cancer screening device, without the
need for laboratory infrastructure, will support the UAR government’s programme of improving the lives of
women in ethnic minorities.
In addition to the 912 hospitals in Xinjiang UAR, there are 16,588 community medical centres, a key target
market for use of the TruScreen device.
TruScreen has recently delivered from its China based manufacturing facility, 20 TruScreen cervical cancer
screening devices, and 12,960 SUS to commence this programme.
TruScreen CEO Juliet Hull said: “with a population of over 1.4 billion people, China remains the most
established and significant market for TruScreen. The strategic decision to establish a manufacturing, together
with service and recalibration facilities in China, is providing our distributor with the competitive advantage to
expand their market reach within the country, with a locally manufactured device ”.
This announcement has been approved by the Board.
-ENDS-

For more information, visit

www.truscreen.com or contact:
Juliet Hull
Chief Executive Officer
juliethull@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Julia Maguire
Investor Relations
julia@thecapitalnetwork.com.au

+61 2 8999 3699




About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that
has developed an AI-enabled device that can detect precancerous and cancerous cervical changes
in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening
technologies that have only triage/adjunct functionality, the TruScreen device is registered as a
primary screening tool.
TruScreen’s cervical screening technology effectively resolves many of the ongoing issues with
conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the
need for supporting laboratory infrastructure.
The device is CE-marked, meaning it meets EU safety, health and environmental protection standards
required for sale and use throughout Europe. It is also National Medical Products Administration
approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for
devices marketed and sold in China.
TruScreen is currently targeting product sales to a range of low and middle-income countries,
including China, Mexico, Vietnam, Russia, Zimbabwe and Saudi Arabia, where no large-scale cervical
cancer screening programmes and infrastructure are currently in place. By doing so, the Company
hopes to help improve the health and wellbeing of women worldwide.
To learn more, please visit: www.truscreen.com/